Anthera Pharmaceuticals Inc. (Nasdaq: ANTH) reported disappointing results from a Phase 3 study of blisibimod to treat systemic lupus erythematosus sending the stock price down 88 cents to close at $1.90.
Disappointing study results for Anthera Pharmaceuticals
November 10, 2016 at 18:44 PM EST